Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $455,468.40 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the transaction, the insider directly owned 22,693 shares in the company, valued at approximately $410,743.30. This represents a 52.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Edmund Dunn also recently made the following trade(s):

• On Monday, March 2nd, Edmund Dunn sold 536 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $17.50, for a total value of $9,380.00.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $18.61 on Thursday. The stock has a market capitalization of $1.21 billion, a P/E ratio of 58.16 and a beta of 1.63. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.50 and a 52 week high of $25.77. The stock has a fifty day moving average of $19.97 and a 200-day moving average of $13.90.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several large investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new stake in shares of Monte Rosa Therapeutics in the 3rd quarter valued at $379,000. Squarepoint Ops LLC bought a new position in Monte Rosa Therapeutics during the second quarter worth about $803,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Monte Rosa Therapeutics in the third quarter worth about $182,000. Bailard Inc. acquired a new stake in shares of Monte Rosa Therapeutics during the second quarter worth about $101,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Monte Rosa Therapeutics during the 2nd quarter valued at about $89,000. Institutional investors own 79.96% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on GLUE shares. Wells Fargo & Company upped their target price on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Guggenheim raised their price objective on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Piper Sandler reiterated an “overweight” rating and set a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $31.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Monte Rosa Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $31.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.